Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia

Atherosclerosis

Volumn 216, Issue 2, 2011, Pages 426-432

  Nenseter, Marit S ^a   Lindvig, Henriette Walaas ^a,b   Ueland, Thor ^a   Langslet, Gisle ^a   Ose, Leiv ^a,b   Holven, Kirsten B ^b   Retterstøl, Kjetil ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

CHD; Familial hypercholesterolemia; Lp(a)

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; DISEASE PREDISPOSITION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; COHORT STUDIES; CORONARY DISEASE; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEIN(A); MALE; MIDDLE AGED; PHENOTYPE; RISK; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS;

EID: 79958004985     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.02.007     Document Type: Article

References (36)

1. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232:34-47.
2. Austin M.A., Hutter C.M., Zimmern R.L., Humphries S.E. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am. J. Epidemiol. 2004, 160:407-420.
3. Weisgraber K.H., Innerarity T.L., Newhouse Y.M., et al. Familial defective apolipoprotein B-100: enhanced binding of monoclonal antibody MB47 to abnormal low density lipoproteins. Proc Natl Acad Sci USA 1988, 85:9758-9762.
4. Scientific Steering Committee on behalf of the Simon Broome Register Group, Risk of fatal coronary heart disease in familial hypercholesterolaemia, Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991;303:893-6.
5. Jansen A.C., van Wissen S., Defesche J.C., Kastelein J.J. Phenotypic variability in familial hypercholesterolaemia: an update. Curr. Opin. Lipidol. 2002, 13:165-171.
6. Civeira F. International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004, 173:55-68.
7. Ferrieres J., Lambert J., Lussier-Cacan S., Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation 1995, 92:290-295.
8. Berg K. A new serum type system in man-the Lp system. Acta Pathol. Microbiol. Scand. 1963, 59:369-382.
9. Danesh J., Collins R., Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000, 102:1082-1085.
10. Berglund L., Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2219-2226.
11. Bennet A., Di Angelantonio E., Erqou S., et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch. Intern. Med. 2008, 168:598-608.
12. Sawabe M., Tanaka N., Nakahara K., et al. High lipoprotein(a) level promotes both coronary atherosclerosis and myocardial infarction: a path analysis using a large number of autopsy cases. Heart 2009, 95:1997-2002.
13. Emerging Risk Factors Collaboration, Erqou S., Kaptoge S., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412-423.
14. Seed M., Hoppichler F., Reaveley D., et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N. Engl. J. Med. 1990, 322:1494-1499.
15. Lingenhel A., Kraft H.G., Kotze M., et al. Concentrations of the atherogenic Lp(a) are elevated in FH. Eur. J. Hum. Genet. 1998, 6:50-60.
16. Jansen A.C., van Aalst-Cohen E.S., Tanck M.W., et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J. Intern. Med. 2004, 256:482-490.
17. Holmes D.T., Schick B.A., Humphries K.H., Frohlich J. Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin. Chem. 2005, 51:2067-2073.
18. Erqou S., Thompson A., Di Angelantonio E., et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010, 55:2160-2167.
19. Armstrong V.W., Cremer P., Eberle E., et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis 1986, 62:249-257.
20. Kostner G.M., Avogaro P., Cazzolato G., Marth E., Bittolo-Bon G., Qunici G.B. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981, 38:51-61.
21. Nielsen L.B., Nordestgaard B.G., Stender S., Niendorf A., Kjeldsen K. Transfer of lipoprotein(a) and LDL into aortic intima in normal and in cholesterol-fed rabbits. Arterioscler. Thromb. Vasc. Biol. 1995, 15:1492-1502.
22. Deb A., Caplice N.M. Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis. Clin. Cardiol. 2004, 27:258-264.
23. Kamstrup P.R. Lipoprotein(a) and ischemic heart disease--a causal association? A review. Atherosclerosis 2010, 211:15-23.
24. Tsimikas S., Brilakis E.S., Miller E.R., et al. Oxidized phospholipids. Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 2005, 353:46-57.
25. Carlson L.A., Hamsten A., Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J. Intern. Med. 1989, 226:271-276.
26. Suk Danik J., Rifai N., Buring J.E., Ridker P.M. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J. Am. Coll. Cardiol. 2008, 52:124-131.
27. Marcovina S.M., Albers J.J., Scanu A.M., et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin. Chem. 2000, 46:1956-1967.
28. Hopkins P.N., Stephenson S., Wu L.L., Riley W.A., Xin Y., Hunt S.C. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol. 2001, 87:547-553.
29. de Sauvage Nolting P.R., Defesche J.C., Buirma R.J., Hutten B.A., Lansberg P.J., Kastelein J.J. Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J. Intern. Med. 2003, 253:161-168.
30. Alonso R., Mata N., Castillo S., et al. Spanish familial hypercholesterolaemia group cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis 2008, 200:315-321.
31. Volpato S., Vigna G.B., McDermott M.M., et al. Lipoprotein(a), inflammation, and peripheral arterial disease in a community-based sample of older men and women (the InCHIANTI study). Am. J. Cardiol. 2010, 105:1825-1830.
32. Nordestgaard B.G., Chapman M.J., Ray K., et al. For the European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 2010, 31:2844-2853.
33. Nicholls S.J., Tang W.H., Scoffone H., et al. Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. J. Lipid Res. 2010, 51:3055-3061.
34. Kamstrup P.R., Benn M., Tybjaerg-Hansen A., Nordestgaard B.G. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the copenhagen city heart study. Circulation 2008, 117:176-184.
35. Murase T., Okubo M., Amemiya-Kudo M., et al. Impact of markedly elevated serum lipoprotein(a) levels (≥100mg/dL) on the risk of coronary heart disease. Metabolism. 2007, 56:1187-1191.
36. Boerwinkle C., Leffert C., Lin J., Lackner C., Chiesa G., Hobbs H.H. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J. Clin. Invest. 1992, 90:52-60.